Cardioprotective Activity of Linga Mathirai in Rodents

Abstract

Ischemic Heart Disease remains the major cause of mortality in both developed and developing countries. Myocardial infarction is the rapid development of ischemic necrosis of myocardium. Atherosclerosis in coronary artery accounts for myocardial ischemia in more than 90% cases. The present research work 1s an attempt to characterize a Siddha Sastric formulation - Linga Mathirai and to validate the Cardioprotective effect of Linga Mathirai against Isoproterenol induced myocardial infarction and Vitamin B3 based atherogenic diet induced atherosclerosis in Sprague newlinedawley rats by estimating the biochemical markers and histopathological studies. The data of the research showed that Linga Mathirai at the dosage of 11 mg/kg body weight in rats modulated most of the biochemical parameters and histopathological lesions to near to the normal status and assuring its cardioprotective role. Linga Mathirai has been scientifically studied and validated to use as a drug in the management of Ischemic Heart Disease at the intended therapeutic dose 130 mg/kg twice daily cited in the literature along with the adjuvant dried ginger decoction. From the above studies, it can be concluded as follows: 1. Linga Mathirai has long shelf life period and free from toxins, and it contains metallic group specifically mercury attached with sulphur. 2. Median lethal dose for Linga Mathirai was calculated as more than 2000 mg/kg body weight. 3. No observed effect level (NOEL) of Linga Mathirai prepared by us to Sprague Dawley Rats through oral route over a period of 90 days was found to be 110 mg/kg body weight for both male and female rats. 4. Linga Mathirai demonstrated no significant clot lytic property in different rat blood samples on compared with low molecular weight haeparin but the study revealed that LM have antiplatelet aggregation property. It can be concluded that Linga Mathirai show better thrombolytic activity but not so better efficacy as low molecular weight heparin. newline newline